William Soscia, MD
Ophthalmology · University Park, FLNPI 1518965516
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $55,886 of the $68,447 with a category attached, or 81.6%. Johnson & Johnson Surgical Vision, Inc. accounts for 66.1% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $33,154 and has fallen 78.0% since, to $7,298 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $407.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$45K
- Lensar, Inc.$17K
- Rxsight Inc$4K
- Alcon$789
- Bausch & Lomb Americas Inc.$252
- AbbVie$242
- plus $1K from 11 others
Across 22 payments — averaging $15,767 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Surgical Vision, Inc.$270K
- Rxsight Inc$60K
- Ethicon Endo-surgery Inc.$16K
What the payments were for
- Consulting fees$55,88682%
- Speaking & faculty fees$3,2885%
- Food & beverage$9,27214%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 74 | $45,237 |
| Lensar, Inc. | 13 | $16,678 |
| Rxsight Inc | 9 | $4,116 |
| Alcon | 20 | $789 |
| Bausch & Lomb Americas Inc. | 6 | $252 |
| AbbVie(2 entities) | 6 | $242 |
| Sun Pharmaceutical Industries Inc. | 4 | $187 |
| Glaukos Corporation | 4 | $168 |
| Novartis | 9 | $168 |
| Rayner Intraocular Lenses Limited | 9 | $154 |
| Tarsus Pharmaceuticals, Inc. | 2 | $151 |
| Apellis Pharmaceuticals, Inc. | 1 | $106 |
| Sight Sciences, Inc. | 4 | $68 |
| Ocular Therapeutix, Inc. | 3 | $54 |
| Omeros Corporation | 2 | $38 |
| Kala Pharmaceuticals, Inc. | 1 | $23 |
| Halozyme Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$47,622
- LENSAR LASER SYSTEM$16,479
- RXSIGHT CONTACT LENS$4,005
- RXSIGHT INJECTOR CARTRIDGE$4,005
- RXSIGHT INJECTOR HANDPIECE$4,005
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$4,005
- LIGHT ADJUSTABLE LENS (LAL)$3,756
- Tecnis Simplicity$398
- VERITAS Vision System$263
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$249
- ILUX$148
- CEQUA$125
- DURYSTA$124
- MIEBO$122
- XDEMVY$122
- Catalys Laser System$120
- Syfovre$106
How this compares
$68,447 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 31 | $42,079 |
| RestasisCyclosporine | 22 | $22,486 |
| Prednisolone Acetate | 493 | $18,552 |
| MieboPerfluorohexyloctane/Pf | 23 | $18,494 |
| Lotemax SmLoteprednol Etabonate | 49 | $13,273 |
| Cyclosporine | 19 | $6,458 |
| MoxifloxacinMoxifloxacin Hcl | 191 | $3,352 |
| Ketorolac Tromethamine | 216 | $3,142 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 20 | $2,469 |
| Loteprednol Etabonate | 14 | $2,359 |
| Brimonidine Tartrate | 12 | $2,084 |
| Latanoprost | 15 | $250 |
| ErythromycinErythromycin Base | 18 | $152 |
| Tobramycin | 30 | $122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $252 | $60,57354 claims |
| AbbVieRestasis | $242 | $22,48622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in University Park
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.